Pharmacokinetics, pharmacodynamics, and safety of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, in healthy subjects when administered in co-mixture with recombinant human hyaluronidase: A phase 1 randomized trial.
Almasa BassAnna PlotkaKhurshid MridhaCatherine SattlerAlbert M KimDavid R PlowchalkPublished in: Health science reports (2018)
ClinicalTrials.gov, NCT02667223.